Kite announces acquisition of Interius BioTherapeutics for $350m
The acquisition enhances Kite's cell therapy capabilities by integrating Interius BioTherapeutics’ platform for direct in vivo CAR T-cell generation.
A leading resource for the Pharmaceutical industry since 2002
The acquisition enhances Kite's cell therapy capabilities by integrating Interius BioTherapeutics’ platform for direct in vivo CAR T-cell generation.